FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT ID: NCT00769288
Last Updated: 2014-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
12 participants
INTERVENTIONAL
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Benzoylphenylurea in Treating Patients With Advanced Cancer
NCT00010205
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors
NCT02792465
Benzoylphenylurea in Treating Patients With Advanced Solid Tumors
NCT00016354
AFP464 in Treating Patients With Advanced Solid Tumors
NCT00369200
Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
NCT00559156
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To assess the safety and tolerability of FAU in patients with advanced solid tumors or lymphoma.
II. To determine the dose-limiting toxicity and maximum tolerated dose (MTD) of FAU in these patients.
SECONDARY OBJECTIVES:
I. To observe the clinical response in patients treated with FAU. II. To characterize the pharmacokinetics of FAU in these patients. III. To explore whether an association exists between pre-treatment 18F-FAU PET standardized uptake value levels and time to tumor progression after treatment with unlabeled FAU.
IV. To estimate the protein levels of thymidylate synthase (TS) in archival tumor tissue samples and to compare them with thymidine kinase (TK) and TS protein levels and TK and TS mRNA levels in fresh tumor tissue samples from patients treated at the MTD.
V. To explore the relationship between genetic polymorphisms of TS and tumor 18F-FAU uptake.
OUTLINE: This is a multicenter study.
Patients receive FAU IV over 1 hour on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed for 30 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
I
Patients will receive a 1-hour infusion of FAU on days 1-5.
2'-F-ara-deoxyuridine
Given IV
positron emission tomography
Correlative studies
laboratory biomarker analysis
Correlative studies
pharmacological study
Correlative studies
pharmacogenomic studies
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
2'-F-ara-deoxyuridine
Given IV
positron emission tomography
Correlative studies
laboratory biomarker analysis
Correlative studies
pharmacological study
Correlative studies
pharmacogenomic studies
Correlative studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Archival tumor tissue sample available for correlative pharmacodynamic and pharmacogenomic studies
* Accessible tumor tissue available (for patients enrolled in the expanded maximum tolerated dose \[MTD\] cohort)
* No known active brain metastases but previously treated brain metastases allowed
* ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%
* AST and ALT =\< 2.5 times upper limit of normal (ULN) (=\< 5 times ULN if liver metastases are present)
* Alkaline phosphatase =\< 2.0 times ULN (=\< 5 times ULN if bone or liver metastases are present)
* Bilirubin normal
* Creatinine normal or creatinine clearance \>= 60 mL/min
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* Willing to undergo tumor biopsies for correlative pharmacodynamic studies (for patients enrolled in the expanded MTD cohort)
* Able to lie still for PET scan
* Weight =\< 300 lbs
* No uncontrolled illness including, but not limited to, any of the following:
* Ongoing or active infection
* Symptomatic congestive heart failure
* Unstable angina pectoris
* Cardiac arrhythmia
* Psychiatric illness/social situation that would preclude compliance with study requirements
* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to FAU
* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin C, or bleomycin), immunotherapy, or experimental therapy and recovered
* More than 4 weeks since prior radiotherapy to \> 5% of total marrow volume
* No prior radiotherapy to \>= 50% of total marrow volume
* More than 3 weeks since prior radiotherapy to =\< 5% of total marrow volume
* No other concurrent investigational agents
* ANC \>= 1,500/mm\^3
* Platelet count \>= 100,000/mm\^3
* Life expectancy \> 12 weeks
* Histologically or cytologically confirmed malignant solid tumor for which standard curative or palliative measures do not exist or are no longer effective
* Solid hematologic malignancies (e.g., Hodgkin or non-Hodgkin lymphoma) allowed provided bone marrow biopsy has been performed within the past 6 weeks
* Metastatic or unresectable disease
* No other concurrent anticancer therapy (e.g., cytotoxic therapy, biologic therapy, radiotherapy, or hormonal therapy)
* Concurrent hormone replacement therapy allowed
* Concurrent megestrol acetate or bisphosphonates allowed provided they were started 1 month prior to study enrollment
* Concurrent luteinizing hormone-releasing hormone agonists to maintain castrate levels of testosterone allowed for patients with prostate cancer
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patricia LoRusso
Role: PRINCIPAL_INVESTIGATOR
Wayne State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wayne State University
Detroit, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2009-00248
Identifier Type: REGISTRY
Identifier Source: secondary_id
CDR0000615651
Identifier Type: -
Identifier Source: secondary_id
WSU#2007-005
Identifier Type: -
Identifier Source: secondary_id
WSU-2007-005
Identifier Type: OTHER
Identifier Source: secondary_id
7916
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2009-00248
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.